TGF-β Inhibitors for Therapeutic Management of Kidney Fibrosis

Cheol Ho Park; Tae Hyun Yoo

doi:10.3390/ph15121485

TGF-β Inhibitors for Therapeutic Management of Kidney Fibrosis

Cheol Ho Park, Tae Hyun Yoo

Department of Internal Medicine

Research output: Contribution to journal › Review article › peer-review

2 Citations (Scopus)

Abstract

Kidney fibrosis is a common pathophysiological mechanism of chronic kidney disease (CKD) progression caused by several underlying kidney diseases. Among various contributors to kidney fibrosis, transforming growth factor-β1 (TGF-β1) is the major factor driving fibrosis. TGF-β1 exerts its profibrotic attributes via the activation of canonical and non-canonical signaling pathways, which induce proliferation and activation of myofibroblasts and subsequent accumulation of extracellular matrix. Over the past few decades, studies have determined the TGF-β1 signaling pathway inhibitors and evaluated whether they could ameliorate the progression of CKD by hindering kidney fibrosis. However, therapeutic strategies that block TGF-β1 signaling have usually demonstrated unsatisfactory results. Herein, we discuss the therapeutic concepts of the TGF-β1 signaling pathway and its inhibitors and review the current state of the art regarding regarding TGF-β1 inhibitors in CKD management.

Original language	English
Article number	1485
Journal	Pharmaceuticals
Volume	15
Issue number	12
DOIs	https://doi.org/10.3390/ph15121485
Publication status	Published - 2022 Dec

Bibliographical note

Publisher Copyright:
© 2022 by the authors.

All Science Journal Classification (ASJC) codes

Molecular Medicine
Pharmaceutical Science
Drug Discovery

Access to Document

10.3390/ph15121485

Cite this

@article{9bbe115aa50345b687631178182290d4,

title = "TGF-β Inhibitors for Therapeutic Management of Kidney Fibrosis",

abstract = "Kidney fibrosis is a common pathophysiological mechanism of chronic kidney disease (CKD) progression caused by several underlying kidney diseases. Among various contributors to kidney fibrosis, transforming growth factor-β1 (TGF-β1) is the major factor driving fibrosis. TGF-β1 exerts its profibrotic attributes via the activation of canonical and non-canonical signaling pathways, which induce proliferation and activation of myofibroblasts and subsequent accumulation of extracellular matrix. Over the past few decades, studies have determined the TGF-β1 signaling pathway inhibitors and evaluated whether they could ameliorate the progression of CKD by hindering kidney fibrosis. However, therapeutic strategies that block TGF-β1 signaling have usually demonstrated unsatisfactory results. Herein, we discuss the therapeutic concepts of the TGF-β1 signaling pathway and its inhibitors and review the current state of the art regarding regarding TGF-β1 inhibitors in CKD management.",

author = "Park, {Cheol Ho} and Yoo, {Tae Hyun}",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = dec,

doi = "10.3390/ph15121485",

language = "English",

volume = "15",

journal = "Pharmaceuticals",

issn = "1424-8247",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "12",

}

TY - JOUR

T1 - TGF-β Inhibitors for Therapeutic Management of Kidney Fibrosis

AU - Park, Cheol Ho

AU - Yoo, Tae Hyun

PY - 2022/12

Y1 - 2022/12

N2 - Kidney fibrosis is a common pathophysiological mechanism of chronic kidney disease (CKD) progression caused by several underlying kidney diseases. Among various contributors to kidney fibrosis, transforming growth factor-β1 (TGF-β1) is the major factor driving fibrosis. TGF-β1 exerts its profibrotic attributes via the activation of canonical and non-canonical signaling pathways, which induce proliferation and activation of myofibroblasts and subsequent accumulation of extracellular matrix. Over the past few decades, studies have determined the TGF-β1 signaling pathway inhibitors and evaluated whether they could ameliorate the progression of CKD by hindering kidney fibrosis. However, therapeutic strategies that block TGF-β1 signaling have usually demonstrated unsatisfactory results. Herein, we discuss the therapeutic concepts of the TGF-β1 signaling pathway and its inhibitors and review the current state of the art regarding regarding TGF-β1 inhibitors in CKD management.

AB - Kidney fibrosis is a common pathophysiological mechanism of chronic kidney disease (CKD) progression caused by several underlying kidney diseases. Among various contributors to kidney fibrosis, transforming growth factor-β1 (TGF-β1) is the major factor driving fibrosis. TGF-β1 exerts its profibrotic attributes via the activation of canonical and non-canonical signaling pathways, which induce proliferation and activation of myofibroblasts and subsequent accumulation of extracellular matrix. Over the past few decades, studies have determined the TGF-β1 signaling pathway inhibitors and evaluated whether they could ameliorate the progression of CKD by hindering kidney fibrosis. However, therapeutic strategies that block TGF-β1 signaling have usually demonstrated unsatisfactory results. Herein, we discuss the therapeutic concepts of the TGF-β1 signaling pathway and its inhibitors and review the current state of the art regarding regarding TGF-β1 inhibitors in CKD management.

UR - http://www.scopus.com/inward/record.url?scp=85144724658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85144724658&partnerID=8YFLogxK

U2 - 10.3390/ph15121485

DO - 10.3390/ph15121485

M3 - Review article

AN - SCOPUS:85144724658

SN - 1424-8247

VL - 15

JO - Pharmaceuticals

JF - Pharmaceuticals

IS - 12

M1 - 1485

ER -

TGF-β Inhibitors for Therapeutic Management of Kidney Fibrosis

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this